Topics › Science

Science2019globalhigh confidence

In a small (n=9) phase I open-label clinical trial, a 3-day oral course of dasatinib plus quercetin reduced senescent-cell markers in adipose tissue and skin of people with diabetic kidney disease.

Sources

More in Science

All science facts →